Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06349148
Other study ID # NESTLE2022QN-0007
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 1, 2024
Est. completion date December 2025

Study information

Verified date March 2024
Source Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Contact SHUANGZHENG JIA, PhD
Phone 00-86-010-87788276
Email jiashuangzheng@cicams.ac.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this open-label randomized control trial is to study the effect of immunonutrition in locally advanced cervical cancer (LACC) with standard concurrent chemoradiotherapy. LACC patients undergoing radical synchronous chemoradiotherapy will be randomized into the experimental group receiving enteral immunonutrition therapy and the control group receiving standard enteral nutrition support.The main purpose it aims to answer are:1)Can immunonutrition therapy improve patients' dose-limiting toxicity(DLT) and DLT-free survival? 2)Can immunonutrition therapy improve patients' nutritional status and quality of life?


Description:

Malnutrition is one of the most common complications in patients with Locally Advanced Cervical Cancer (LACC) undergoing radical concurrent chemoradiotherapy (CCRT). Tumor patients often experience significant immune imbalance, metabolic abnormalities, and inflammatory responses. Immunonutrition therapy involves the use of specific immunonutrients such as polyunsaturated fatty acids, arginine, nucleotides, etc., to prevent and correct malnutrition in cancer patients, regulate immune function, alleviate harmful or excessive inflammatory responses, and thereby improve patients' clinical outcomes. This study is an open-label randomized controlled trial, including patients with LACC who all receive radical radiotherapy. Using the Nutritional Risk Screening 2002 (NRS2002) at screening, patients identified as having nutritional risk are further assessed by nutritionists and physicians using the Patient-Generated Subjective Global Assessment (PG-SGA) score and modified Global leadership initiative on malnutrition (GLIM) criteria. Patients with moderate or severe malnutrition are randomly allocated into the enteral immunonutrition therapy group (experimental group) and the standard enteral nutrition support group (control group). The experimental group receives immunonutrients per day, while the control group receives isoenergetic standard oral enteral nutrition. Upon admission, all patients receive nutritional education from specialized nurses and consult with nutritionists, and nutritional support is provided during the concurrent chemoradiotherapy for a total of 5 weeks (W0-W5).GLIM score, quality of life score and peripheral blood inflammation and immune indicators were collected within 48 hours after admission (before treatment), W5, W8, and W20; CTCAE v 5.0 score was used for treatment side effects.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date December 2025
Est. primary completion date August 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years; - Pathological histological diagnosis confirmed as cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma; - Confirmed as Locally Advanced Cervical Cancer (LACC) based on gynecological examination and imaging assessment; - Undergoing CCRT/RT treatment; - Patients are conscious, able to communicate without barriers, and able to answer questions. - diagnosed with malnutrition according to the GLIM criteria; Exclusion Criteria: - Patients who received neoadjuvant chemotherapy or immunotherapy before treatment; - Patients with concomitant other malignant tumors or a history of malignant tumors; - Patients with special pathological types of tumors such as cervical small cell carcinoma or neuroendocrine tumors; - Patients staged as ?b according to the International Federation of Gynecology and Obstetrics(FIGO) 2018 staging system; - Patients with other severe chronic debilitating diseases, such as severe heart failure (New York Heart Association Class II-IV), severe liver damage (alanine aminotransferase = 3 times the upper limit of normal), severe renal insufficiency (GFR < 30 ml/min*1.73 m²), etc.; - Eastern Cooperative Oncology Group(ECOG) performance status = 2; - Presence of other contraindications to CCRT/RT.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
enteral immunonutrition
Patients in this group receives 2 bottles of immunonutrients per day (Impact, Nestlé, approximately 700 kcal).
standard oral enteral nutrition
Patients in the control group receives isoenergetic standard oral enteral nutrition ( emulsion or Nutrison).

Locations

Country Name City State
China Cancer Hospital, Chinese Academy of Medical Sciences Beijing

Sponsors (1)

Lead Sponsor Collaborator
SHUANGZHENGJIA

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose-limiting toxicity Patients need to receive cisplatin treatment at 40 mg/m2 weekly for 5-6 weeks. During this period, any serious adverse reactions that lead to treatment interruption, delay, or chemotherapy dose reduction are defined as dose-limiting toxicities(DLT). 5-6 weeks
Primary DLT-free survival Time from start of treatment to onset of DLT 5-6 weeks
Secondary compliance the proportion of people who complete the prescribed treatment plan 5-6 weeks
Secondary Prevalence of malnutrition assessed by GLIM criteria 5-6 weeks, 3 months post-treatment
Secondary Prevalence of sarcopenia assessed by Skeletal muscle index(SMI) at the third lumbar vertebra(L3-SMI )calculated based on CT 5-6 weeks, 3 months post-treatment
Secondary QoL (Quality of life) Quality of life measured by standardized EORTC quality of life questionnaire(QLQ)-C30 5-6 weeks, 3 months post-treatment
Secondary Objective response rate (ORR) evaluated by RECIST 3 months post-treatment
Secondary laboratory tests inflammation and immune-related indicators 5-6 weeks, 3 months post-treatment
Secondary 2-year overall survival the time from the start of treatment until the date of death from any cause 2 years
Secondary 2-year progression-free survival the date of the treatment to the date of disease progression or death from any cause in the absence of progression 2 years
See also
  Status Clinical Trial Phase
Completed NCT03676101 - Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females Phase 1
Completed NCT00189410 - Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and Carboplatin in Malignant Gynecologic Tumours Phase 2
Recruiting NCT06416696 - Toripalimab for High-risk Locally Advanced Cervical Cancer Phase 2
Completed NCT01097252 - Weekly Versus Three-week Chemoradiation in Patients With Advanced Cervical Cancer Phase 3
Completed NCT01047345 - A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006) Phase 3
Completed NCT00943722 - A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002) Phase 3